Core Scientific (CORZ) Common Equity (2020 - 2026)

Core Scientific has disclosed Common Equity across 7 years of filings, most recently posting -$1.3 billion for Q1 2026.

• Common Equity for Q1 2026 came in at -$1.3 billion, down 322.8% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.3 billion (down 322.8% YoY), and the FY2025 annual result was -$962.7 million, down 2.09% from the prior year.
• Common Equity came in at -$1.3 billion for Q1 2026 at Core Scientific, down from -$962.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.1 billion in Q1 2022 to a low of -$1.3 billion in Q1 2026.
• The 5-year median for Common Equity is -$418.7 million (2023), against an average of -$522.9 million.
• Across the five-year window, Common Equity surged 1059.68% in 2022 and slumped 673.39% in 2023, its largest moves.
• Core Scientific's Common Equity stood at -$409.3 million in 2022, then slumped by 45.83% to -$596.9 million in 2023, then plunged by 57.98% to -$943.0 million in 2024, then declined by 2.09% to -$962.7 million in 2025, then tumbled by 35.62% to -$1.3 billion in 2026.
• The last three Common Equity figures came in at -$1.3 billion (Q1 2026), -$962.7 million (Q4 2025), and -$1.3 billion (Q3 2025), per Business Quant data.